去甲替林,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1299	*10	The CYP2D610 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D610 allele in combination with a no or decreased function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1298	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D66 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1297	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D65 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1296	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D64 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1295	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D63 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1294	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with nortriptyline may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

等位基因

注释文本

The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1298

The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1297

The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1296

The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1295

The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1294

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with nortriptyline may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

id	证据的ID	总结
1083	1184467243	CYP2D6 3 + 4 + 5 + 6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.
1082	1183617418	CYP2D6 4/4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 1/1.
1081	1183615525	CYP2D6 10/10 is associated with violent psychosis when treated with nortriptyline.
1080	1183615499	CYP2D6 5/10 is associated with increased Constipation, Dizziness and dry mouth when treated with nortriptyline.
1079	1444702163	CYP2D6 poor metabolizers are not associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.
1078	1183683958	CYP2D6 poor metabolizers are associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major.
1077	PA166104961	Annotation of DPWG Guideline for nortriptyline and CYP2D6
1076	PA166104998	Annotation of CPIC Guideline for nortriptyline and CYP2D6

证据的ID

总结

1083

1184467243

CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.

1082

1183617418

CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.

1081

1183615525

CYP2D6 *10/*10 is associated with violent psychosis when treated with nortriptyline.

1080